Biomarkers to Classify Heart Failure (NCT02347722) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Biomarkers to Classify Heart Failure
Canada511 participantsStarted 2015-05
Plain-language summary
The purpose of this study is to evaluate existing biomarkers and see if they can be used to accurately diagnose the etiology of heart failure.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients admitted with symptomatic heart failure, diagnosed within 2 years.
* Diagnosis of congestive heart failure using the modified Framingham criteria:
Simultaneous presence of at least 2 major criteria or 1 major criterion in conjunction with 2 minor criteria or a previous clear diagnosis of heart failure.
Major criteria:
* Paroxysmal nocturnal dyspnea or orthopnea
* Neck vein distention
* Rales/Crackles (\>10 cm from base of lungs)
* Acute pulmonary edema
* S3 gallop
* Increased central venous pressure (\>16 cm H2O at right atrium)
* Hepatojugular reflux
* Weight loss \>4.5 kg in 5 days in response to treatment Echocardiographic left ventricular dysfunction
Minor criteria:
* Bilateral ankle edema
* Nocturnal cough
* Dyspnea on exertion
* Hepatomegaly
* Pleural effusion
* Weight loss \>4.5 kg caused by heart failure where factors other than treatment of CHF could have contributed to the weight loss
* Tachycardia (heart rate \>120 beats/min) Minor criteria are acceptable only if they cannot be attributed to another medical condition (such as pulmonary hypertension, chronic lung disease, cirrhosis, ascites, or the nephrotic syndrome).
Exclusion Criteria:
* Patients unable to provide blood sample
* Patients unable to provide consent
* Patient with life expectancy of less than 6 months, or has major co-morbidities.
* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk becau…
What they're measuring
1
Accuracy of heart failure panel to predict etiology of heart failure using biomarkers.
Timeframe: at end of study
Trial details
NCT IDNCT02347722
SponsorOttawa Heart Institute Research Corporation